March 13, 2018

CUREWIZE, SUCCESSFULY COMPLETED CLINICAL TRIAL ON LAB TEST

Yokneam, Israel – Curewize, Curewize Successfully Completed Clinical Trial on Lab Test Revealing Acute Lymphoblastic Leukemia Patients’ Optimal Treatment Regimen .

November 21, 2016

CUREWIZE, TO PARTICIPATE AND PRESENT RESULTS AT 58TH ASH ANNUAL MEETING & EXPOSITION

Yokneam, Israel – Curewize, today announced that they will be presenting Results at 58th ASH Annual Meeting & Exposition, September 3rd – 6th, 2016, San Diego, CA, USA. showing ProALL microRNA Biomarkers Measured in Blood Predicts Relapse in Pediatric Acute Lymphoblastic Leukemia

Curewize’s is Developing Technology based on findings published in Genes Chromosomes & Cancer (2016) showing microRNA expression in bone marrow sample taken at diagnosis can predict Pediatric Acute Lymphoblastic Leukemia patients risk for relapse.

November 17, 2016

BIOSHAI, WORLD'S FIRST BLOOD TEST TO AID DIAGNOSIS OF PARKINSON'S

Yokneam, Israel – Bioshai, expects to begin commercializing its unique assay in 2019, applying for CE clearance in Europe. You can read more about it in BIOSHAI’S article published in Israel21c

April 14, 2016

CUREWIZE LTD. TO PRESENT AT IATI BIOMED 2016 CONFERENCE IN MAY

Yokneam, Israel, April 14, 2016 – Curewize Ltd., a clinical research and commercialization company aiming to advance the personalized treatment of cancers common to children, adolescents and young adults, announced today that it will provide an overview of its work at Israel’s Biomed conference in May 2016.

April 1, 2016

YOUDIM PHARMACEUTICALS RESTRUCTURES BOARD OF DIRECTORS

Yokneam, Israel, April 1, 2016 – Youdim Pharmaceuticals. Prof. Eliahu Heldman, co-founder of NeuroDerm (Nasdaq: NDRM), shall join the company’s Board of Directors and become a member of its Scientific Advisory Board.